European Medicines Agency (EMA) identifies, capillary leak syndrome (CLS) as a potential side effect of AZ COVID-19 vaccine (Vaxzevria)

While the MHRA has not yet issued official precautionary advice, the EMA has determined that people who have previously been diagnosed with CLS should not receive the AZ vaccine. It is reported that at this point, the MHRA does not see a causal link with the vaccine.

Source:

Biospace Inc.